Please assess the completion status of the following clinical trial:

Trial Title: A Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 14.0

Eligibility Criteria:
Inclusion Criteria:~* Baseline health is stable.~* Has a clinical diagnosis of chronic HCV infection.~Exclusion Criteria:~* Has a history of stroke or chronic seizures.~* Has a history of cancer.~* Has a history of human immunodeficiency virus (HIV) infection.~* Has had major surgery, donated blood or participated in another investigational study within the past 3 months.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 400 mg Grazoprevir - GT1 (Type: EXPERIMENTAL): GT1 HCV-infected Participants: 400 mg Grazoprevir or Placebo
- 600 mg Grazoprevir - GT1 (Type: EXPERIMENTAL): GT1 HCV-infected Participants: 600 mg Grazoprevir or Placebo
- 800 mg Grazoprevir - GT1 (Type: EXPERIMENTAL): GT1 HCV-infected Participants: 800 mg Grazoprevir or Placebo
- 400 mg Grazoprevir - GT3 (Type: EXPERIMENTAL): GT3 HCV-infected Participants: 400 mg Grazoprevir or Placebo
- 600 mg Grazoprevir - GT3 (Type: EXPERIMENTAL): GT3 HCV-infected Participants: 600 mg Grazoprevir or Placebo
- 800 mg Grazoprevir - GT3 (Type: EXPERIMENTAL): GT3 HCV-infected Participants: 800 mg Grazoprevir or Placebo
- 200 mg Grazoprevir - GT1 (Type: EXPERIMENTAL): GT1 HCV-infected Participants: 200 mg Grazoprevir or Placebo
- 100 mg Grazoprevir - GT1 (Type: EXPERIMENTAL): GT1 HCV-infected Participants: 100 mg Grazoprevir or Placebo
- 50 mg Grazoprevir - GT1 (Type: EXPERIMENTAL): GT1 HCV-infected Participants: 50 mg Grazoprevir or Placebo
- 200 mg Grazoprevir - GT3 (Type: EXPERIMENTAL): GT3 HCV-infected Participants: 200 mg Grazoprevir or Placebo
- 100 mg Grazoprevir - GT3 (Type: EXPERIMENTAL): GT3 HCV-infected Participants: 100 mg Grazoprevir or Placebo
- 50 mg Grazoprevir - GT3 (Type: EXPERIMENTAL): GT3 HCV-infected Participants: 50 mg Grazoprevir or Placebo
- 30 mg Grazoprevir - GT1 (Type: EXPERIMENTAL): GT1 HCV-infected Participants: 30 mg Grazoprevir or Placebo
- 10 mg Grazoprevir - GT1 (Type: EXPERIMENTAL): GT1 HCV-infected Participants: 10 mg Grazoprevir or Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).